Calls Purchased on Medivation (MDVN)

Shares of Medivation MDVN are higher on the session by 0.45%, currently trading at $11.27. The stock has been moving largely higher over the past three months, though it is currently trading below the 50-day and 200-day moving averages. Options traders are buying calls on the name today. Though action has been primarily in small lots, overall call volume is now running at 9.94x the daily average with 75% of all calls traded being purchases on the offer. Traders are buying the $10.00, $12.50, and $14.00 strikes in multiple months. Medivation, Inc. is a biopharmaceutical company. The company focuses on the development of small molecule drugs to treat serious diseases. The company's product candidates in clinical development are dimebon, which is in Phase III development for the treatment of Alzheimer's disease and Huntington disease, and MDV3100, which is in Phase III development for the treatment of castration-resistant prostate cancer.